6 news items
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
ZYME
17 Jun 24
&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment," said Paul Moore, Chief Scientific Officer
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
ZYME
10 Jun 24
be removed surgically. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ZYME
11 Apr 24
. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery, development
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
ZYME
8 Apr 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
SNDX
ZYME
28 Mar 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
bmrk46kvmlvuak5stfu7t454zexwmj69lmwmii4vctm4i n9tpq9m1pnunk
ZYME
27 Mar 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
- Prev
- 1
- Next